A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-07-14
Adverse events
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 22); relationship: not assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-09-01 (study day 42); relationship: not assessed
Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-19 (study day 60); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-10-10 (study day 81); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-10-19 (study day 90); relationship: not assessed
Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-10-30 (study day 101); relationship: N
Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-03 (study day 105); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-11-06 (study day 108); relationship: not assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 311); relationship: N
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-13 (study day 357); relationship: not assessed
Data queries
No data queries.